Ariachery C. Ammini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ariachery C. Ammini has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Arvind Gupta
Jaipur Diabetes and Research Centre, Jaipur, India
4 shared publications - Bk Thelma
Department of Genetics University of Delhi South Campus New Delhi India
4 shared publications - Km Prasanna Kumar
Department of Endocrinology and Metabolism, M.S. Ramiah Medical College, Bangalore, India
4 shared publications M L Khurana
Departments of Endocrinology and Psychiatry, All India Institute of Medical Sciences, New Delhi, India
4 shared publications- Pushplata Prasad
Department of Genetics, University of Delhi South Campus, New Delhi, India
4 shared publications - Rajeev Gupta
Department of Medicine, Fortis Escorts Hospital, JLN Marg, Jaipur 302017, India
4 shared publications
Latest Publications
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Eleven base pair (AACACTCTAGC) deletion of SDHB Ex-4 from c.325 to c.335 in the patient with malignant Vaginal Paraganglioma - A case report
Background: Pheochromocytoma (PHEO) and paraganglioma (PGL) are the tumors of adrenal medulla and extra adrenal ganglia respectively. Most of these PHEO/PGL are benign and may become malignant, if remain undiagnosed/untreated for a longer time. Vaginal PGL are extremely rare. There is not much published literature on vaginal PGL. Objective: To carry out biochemical and genetic analysis of the patient with MIBG negative malignant vaginal PGL. Methods: Blood sample was collected from the patient lying supine for at least 30 min. Plasma free metanephrines (MN, NMN and 3-MT) were estimated using HPLC. SDHB, C and D genes were sequenced after amplification from the DNA extracted from peripheral blood. Results: 22 years female attending endocrine clinic complained of headache, palpitation for 6 years. She had visual disturbance for 1 month. She had tender firm mass involving anterior vaginal wall, hard non tender mass along right lateral pelvic wall. Her MIBG scan was done and it was found negative. Her NMN was 6.800 pg/ml (reference range <800 pg/ml). Owing to high NMN levels MIBG and DOTANOC scan was done. MIBG scan was negative and DOTANOC scan showed increased uptake in pelvic mass, along bilateral sympathetic chain and in left femur. MRI showed solid mass arising from proximal vagina extending along right internal iliac vessels.USG abdomen showed B/l polycystic ovaries, vaginal mass 4.5×4.5 cm and Rt. parametrical mass 2.8×2.9. Her genetic analysis showed 11 bp (AACACTCTAGC) deletion of SDHB Ex-4 from c.325 to c.335. Her family history was negative for the disease from maternal and paternal side. Genetic analysis of her family members was also done. Her father was found positive for the same deletion. Conclusion: The biochemical and genetic analysis should be carried out in the patients with MIBG negative imaging. In this case the mutation showed variable expression.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Eleven base pair (AACACTCTAGC) deletion of SDHB Ex-4 from c.325 to c.335 in the patient with malignant Vaginal Paraganglioma - A case report
Background: Pheochromocytoma (PHEO) and paraganglioma (PGL) are the tumors of adrenal medulla and extra adrenal ganglia respectively. Most of these PHEO/PGL are benign and may become malignant, if remain undiagnosed/untreated for a longer time. Vaginal PGL are extremely rare. There is not much published literature on vaginal PGL. Objective: To carry out biochemical and genetic analysis of the patient with MIBG negative malignant vaginal PGL. Methods: Blood sample was collected from the patient lying supine for at least 30 min. Plasma free metanephrines (MN, NMN and 3-MT) were estimated using HPLC. SDHB, C and D genes were sequenced after amplification from the DNA extracted from peripheral blood. Results: 22 years female attending endocrine clinic complained of headache, palpitation for 6 years. She had visual disturbance for 1 month. She had tender firm mass involving anterior vaginal wall, hard non tender mass along right lateral pelvic wall. Her MIBG scan was done and it was found negative. Her NMN was 6.800 pg/ml (reference range <800 pg/ml). Owing to high NMN levels MIBG and DOTANOC scan was done. MIBG scan was negative and DOTANOC scan showed increased uptake in pelvic mass, along bilateral sympathetic chain and in left femur. MRI showed solid mass arising from proximal vagina extending along right internal iliac vessels.USG abdomen showed B/l polycystic ovaries, vaginal mass 4.5×4.5 cm and Rt. parametrical mass 2.8×2.9. Her genetic analysis showed 11 bp (AACACTCTAGC) deletion of SDHB Ex-4 from c.325 to c.335. Her family history was negative for the disease from maternal and paternal side. Genetic analysis of her family members was also done. Her father was found positive for the same deletion. Conclusion: The biochemical and genetic analysis should be carried out in the patients with MIBG negative imaging. In this case the mutation showed variable expression.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Plasma free metanephrine, normetanephrine and 3-methoxytyramine for the differential diagnosis of pheochromocytoma and paraganglioma
Background: Pheochromocytoma (PHEO) and paraganglioma (PGL) of abdominal origin secrete catecholamines which are metabolized to metanephrines. Head-and-neck paraganglioma (HNPGL) are considered as non secretary tumors. Objectives: To find the utility of plasma free metanephrine (MN), normetanephrine (NMN) and 3-methxytyramine (3-MT) for the differential diagnosis PHEO/PGL after excluding MEN2 and VHL patients. Methods: A total of 79 consecutive patients attending the AIIMS clinics based on clinical symptoms, histological findings and MRI reports were diagnosed with PHEO/PGL (benign (n=59), metastatic (n=9), MEN2 (n=7) and VHL (n=4)). 65 healthy age matched subjects were taken as controls. The subjects with MEN2 and VHL were excluded from the study. Plasma free metanephrines (MN, NMN and 3-MT) were estimated in 64 patients with PHEO/PGL by HPLC technique using ECD after solid phase extraction. Results: The results of this study showed that plasma MN and NMN levels were high in 10 and 33% of patients with HNPGL where as in controls plasma MN and NMN were high in 3.9 and 1.5% respectively. The 3-MT was high in 53.3% of the patients as compare to controls (6.2%). In patients with PHEO/abdominal PGL, MN, NMN and 3-MT were high in 48, 96 and 53% respectively. The mean levels of MN, NMN and 3-MT were 167±260, 659±543 and 2.732±4.325 pg/ml respectively in HNPGL and 1.917±3.447, 7.150±11.454 and 4.752±7.329 pg/ml respectively in the patients with PHEO /abdominal PGL as compare to controls (110±195, 255±224 and 590±690) pg/ml respectively. Conclusions: This study concludes that plasma NMN is useful biochemical marker for diagnosis of PHEO/ abdominal PGL after exclusion of patients with MEN2 and VHL, as compared to MN and 3-MT, with high sensitivity (96%) and specificity (98%). Plasma 3-MT can be useful in the identification of patients with HNPGL.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Plasma free metanephrine, normetanephrine and 3-methoxytyramine for the differential diagnosis of pheochromocytoma and paraganglioma
Background: Pheochromocytoma (PHEO) and paraganglioma (PGL) of abdominal origin secrete catecholamines which are metabolized to metanephrines. Head-and-neck paraganglioma (HNPGL) are considered as non secretary tumors. Objectives: To find the utility of plasma free metanephrine (MN), normetanephrine (NMN) and 3-methxytyramine (3-MT) for the differential diagnosis PHEO/PGL after excluding MEN2 and VHL patients. Methods: A total of 79 consecutive patients attending the AIIMS clinics based on clinical symptoms, histological findings and MRI reports were diagnosed with PHEO/PGL (benign (n=59), metastatic (n=9), MEN2 (n=7) and VHL (n=4)). 65 healthy age matched subjects were taken as controls. The subjects with MEN2 and VHL were excluded from the study. Plasma free metanephrines (MN, NMN and 3-MT) were estimated in 64 patients with PHEO/PGL by HPLC technique using ECD after solid phase extraction. Results: The results of this study showed that plasma MN and NMN levels were high in 10 and 33% of patients with HNPGL where as in controls plasma MN and NMN were high in 3.9 and 1.5% respectively. The 3-MT was high in 53.3% of the patients as compare to controls (6.2%). In patients with PHEO/abdominal PGL, MN, NMN and 3-MT were high in 48, 96 and 53% respectively. The mean levels of MN, NMN and 3-MT were 167±260, 659±543 and 2.732±4.325 pg/ml respectively in HNPGL and 1.917±3.447, 7.150±11.454 and 4.752±7.329 pg/ml respectively in the patients with PHEO /abdominal PGL as compare to controls (110±195, 255±224 and 590±690) pg/ml respectively. Conclusions: This study concludes that plasma NMN is useful biochemical marker for diagnosis of PHEO/ abdominal PGL after exclusion of patients with MEN2 and VHL, as compared to MN and 3-MT, with high sensitivity (96%) and specificity (98%). Plasma 3-MT can be useful in the identification of patients with HNPGL.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Clinical and molecular profile of patients with gonadal dysgenesis attending tertiary care hospital.
Introduction: Gonadal dysgenesis (GD) is a congenital disorder which results in defective development of gonads. GD may be due to mutation(s) in any of the genes involved in gonadal development and differentiation. Here we present clinical and molecular profile (SRY and SOX9 gene) of patients with GD at our hospital. Methodology: Detailed clinical examination, karyotyping and molecular analysis of patients was done for SRY and SOX9 gene. The work has been approved by Institute Ethics Committee. A written informed consent was taken from all patients. Results: We had 11 patients (2011–2013) diagnosed with GD. The present age of the patients was 19.0±9.0 years. The age at presentation was 14.8±8.5 years. Cytogenetic studies revealed 46, XY in 9 patients, 46, XX in 1 patient and 45, XO/46, XY in 1 patient. Ultrasonography for localization of gonads was done in eight patients. Four patients had dysgenetic gonad on one side with contralateral streak gonad on the other side, three patients had bilateral dysgenetic gonads and two had bilateral undescended testis. Molecular analysis revealed normal sequence of SRY gene, while as in SOX9 gene a transition of G>T at position 1776 (rs2229989) was found in 6 patients which was absent in controls. Conclusion: The patients with gonadal dysgenesis need detailed molecular evaluation of all the genes involved in gonadal differentiation pathway. Also the base transition at position 1776 of SOX9 gene may alter the tertiary structure of protein.
- 17 April 2014
- Published by Bioscientifica in Endocrine Abstracts
Clinical and molecular profile of patients with gonadal dysgenesis attending tertiary care hospital.
Introduction: Gonadal dysgenesis (GD) is a congenital disorder which results in defective development of gonads. GD may be due to mutation(s) in any of the genes involved in gonadal development and differentiation. Here we present clinical and molecular profile (SRY and SOX9 gene) of patients with GD at our hospital. Methodology: Detailed clinical examination, karyotyping and molecular analysis of patients was done for SRY and SOX9 gene. The work has been approved by Institute Ethics Committee. A written informed consent was taken from all patients. Results: We had 11 patients (2011–2013) diagnosed with GD. The present age of the patients was 19.0±9.0 years. The age at presentation was 14.8±8.5 years. Cytogenetic studies revealed 46, XY in 9 patients, 46, XX in 1 patient and 45, XO/46, XY in 1 patient. Ultrasonography for localization of gonads was done in eight patients. Four patients had dysgenetic gonad on one side with contralateral streak gonad on the other side, three patients had bilateral dysgenetic gonads and two had bilateral undescended testis. Molecular analysis revealed normal sequence of SRY gene, while as in SOX9 gene a transition of G>T at position 1776 (rs2229989) was found in 6 patients which was absent in controls. Conclusion: The patients with gonadal dysgenesis need detailed molecular evaluation of all the genes involved in gonadal differentiation pathway. Also the base transition at position 1776 of SOX9 gene may alter the tertiary structure of protein.
- 20 September 2013
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 81 (9) , 984
5 α-Reductase Type 2 Deficiency — Response to Dihydrotestosterone Gel: Correspondence
- 20 September 2013
- Published by Springer Nature in Indian Journal of Pediatrics
- Vol. 81 (9) , 984
5 α-Reductase Type 2 Deficiency — Response to Dihydrotestosterone Gel: Correspondence
- 19 August 2013
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 29 (12) , 1045-1047
Morning plasma cortisol is low among obese women with polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is the most common cause for androgen excess in women. It is associated with wide variety of metabolic disorders. The present study assessed morning plasma cortisol in women with PCOS. One hundred and ninety seven cases and 55 controls were enrolled for this study. The mean age of patients and controls were 23 ± 5.6 years and 25 ± 4.3 years. One hundred twelve (56%) women with PCOS had BMI >25. Serum cortisol levels were significantly higher in lean PCOS women compared to controls (13.4 ± 5.1 versus 11.3 ± 4.5, p < 0.01) and over-weight PCOS women group (13.4 ± 5.1 versus 9.3 ± 3.2, p < 0.01). There was a trend for less acne and hirsutism with increase in BMI. Morning plasma cortisol was lower among obese women with PCOS. Morning plasma cortisol correlated negatively with BMI in PCOS women with normal glucose tolerance.
- 19 August 2013
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 29 (12) , 1045-1047
Morning plasma cortisol is low among obese women with polycystic ovary syndrome
Polycystic ovary syndrome (PCOS) is the most common cause for androgen excess in women. It is associated with wide variety of metabolic disorders. The present study assessed morning plasma cortisol in women with PCOS. One hundred and ninety seven cases and 55 controls were enrolled for this study. The mean age of patients and controls were 23 ± 5.6 years and 25 ± 4.3 years. One hundred twelve (56%) women with PCOS had BMI >25. Serum cortisol levels were significantly higher in lean PCOS women compared to controls (13.4 ± 5.1 versus 11.3 ± 4.5, p < 0.01) and over-weight PCOS women group (13.4 ± 5.1 versus 9.3 ± 3.2, p < 0.01). There was a trend for less acne and hirsutism with increase in BMI. Morning plasma cortisol was lower among obese women with PCOS. Morning plasma cortisol correlated negatively with BMI in PCOS women with normal glucose tolerance.
- 1 January 2013
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 26 (9-10) , 915-20
Psychosexual outcomes in three siblings with partial androgen insensitivity syndrome: impact of nature versus nurture
There are few reports of adults with disorders of sexual development (DSD). Here we describe the clinical profile and results of psychological assessment of three siblings with 46, XY DSD caused by partial androgen insensitivity syndrome (PAIS). The elder sibling (aged 22 years) was reared as female, while the middle and youngest siblings (17 and 18 years of age), were reared as males. The gender identity was concordant with the sex of rearing. There was no gender dysphoria. The psychological distress that our patients experienced was due to the limitations placed on them by their medical condition. It did not permit them to experience various facets of being either male or female completely. The younger siblings reared as males had additional problems of gynecomastia and lack of male secondary sexual development.
- 1 January 2013
- Published by Walter de Gruyter GmbH in Journal of Pediatric Endocrinology and Metabolism
- Vol. 26 (9-10) , 915-20
Psychosexual outcomes in three siblings with partial androgen insensitivity syndrome: impact of nature versus nurture
There are few reports of adults with disorders of sexual development (DSD). Here we describe the clinical profile and results of psychological assessment of three siblings with 46, XY DSD caused by partial androgen insensitivity syndrome (PAIS). The elder sibling (aged 22 years) was reared as female, while the middle and youngest siblings (17 and 18 years of age), were reared as males. The gender identity was concordant with the sex of rearing. There was no gender dysphoria. The psychological distress that our patients experienced was due to the limitations placed on them by their medical condition. It did not permit them to experience various facets of being either male or female completely. The younger siblings reared as males had additional problems of gynecomastia and lack of male secondary sexual development.
- 6 March 2012
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 28 (10) , 823-826
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome – a retrospective analysis
Background: Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome. We analyzed the effect of 6 months of therapy with these drugs on body weight and glucose tolerance. Results: This was a retrospective analysis of polycystic ovarian syndrome (PCOS) cases on treatment. There were 88 patients with PCOS-42 were on metformin 1 g daily and 46 were taking spironolactone 50–75 mg daily. 21 of 42 had abnormal glucose tolerance (AGT) in the metformin group and 13 of 46 had AGT in the spironolactone group. Patients on metformin reported a greater reduction in body weight, whereas there was no change in body weight with spironolactone therapy (67.6–63.7 versus 59.6–59.2 kg). There was a significant reduction in the 1 and 2 h glucose and insulin levels with metformin therapy in those with AGT. However, fasting glucose increased in those with normal glucose tolerance. There was no change in either body weight or insulin levels with spironolactone. But, there was a significant reduction in both the 0 and 2 h glucose with spironolactone also in those with AGT. Conclusion: Spironolactone and metformin had similar effect in reducing the glucose levels in PCOS patients with AGT. PCOS patients with normal glucose tolerance had higher fasting plasma glucose at the end of 6 months of metformin therapy inspite of weight reduction.
- 6 March 2012
- Published by Taylor & Francis in Gynecological Endocrinology
- Vol. 28 (10) , 823-826
Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome – a retrospective analysis
Background: Metformin (an insulin sensitizer) and spironolactone (an antiandrogen) are both used for treatment of polycystic ovary syndrome. We analyzed the effect of 6 months of therapy with these drugs on body weight and glucose tolerance. Results: This was a retrospective analysis of polycystic ovarian syndrome (PCOS) cases on treatment. There were 88 patients with PCOS-42 were on metformin 1 g daily and 46 were taking spironolactone 50–75 mg daily. 21 of 42 had abnormal glucose tolerance (AGT) in the metformin group and 13 of 46 had AGT in the spironolactone group. Patients on metformin reported a greater reduction in body weight, whereas there was no change in body weight with spironolactone therapy (67.6–63.7 versus 59.6–59.2 kg). There was a significant reduction in the 1 and 2 h glucose and insulin levels with metformin therapy in those with AGT. However, fasting glucose increased in those with normal glucose tolerance. There was no change in either body weight or insulin levels with spironolactone. But, there was a significant reduction in both the 0 and 2 h glucose with spironolactone also in those with AGT. Conclusion: Spironolactone and metformin had similar effect in reducing the glucose levels in PCOS patients with AGT. PCOS patients with normal glucose tolerance had higher fasting plasma glucose at the end of 6 months of metformin therapy inspite of weight reduction.
- 1 July 2011
- Published by Springer Nature in Hormones
- Vol. 10 (3) , 222-229
Cushing’s disease: Results of treatment and factors affecting outcome
To analyze the therapeutic results of intervention and the factors affecting the outcome of patients with Cushing's disease (CD) cared for at the All Indian Institute of Medical Science (AIIMS), New Delhi. Patients with Cushing's disease treated at a teritiary care centre from January 2000 to December 2009 were prospectively studied. Ninety-seven patients received treatment for CD during this period. Mean duration of follow-up was 3.4 ± 2.2 (mean ± SD) years. Eighty-one patients (83.5%) underwent transsphenoidal surgery (TSS) as the primary treatment modality. Fifty-four patients (66.7%) went into remission after initial TSS; ten (18.5%) of them relapsed after a mean follow-up period of 2.9 ± 2.1 (mean ± SD) years. Histopathologic examination of resected tissue showed corticotroph adenoma in 48 of the 54 (88.9%) who went into remission and 17 of the 27 (63.0%) who did not go into remission after the initial TSS. Sixteen patients with severe hypercortisolism underwent bilateral adrenalectomy (BA) as a life-saving measure which was followed by pituitary surgery 6 to 12 months later. Five patients including one with a large macroadenoma required three or more procedures to achieve eucortisolism. Fifty-four out of 81 (66.7%) of our patients with CD had remission following initial TSS, ten of whom relapsed later on. Sixteen patients unerwent BA as a life-saving procedure. Factors affecting outcome were, age, gender, low dose dexamethasone suppression test cortisol value and histologic confirmation of corticotroph adenoma.
- 1 July 2011
- Published by Springer Nature in Hormones
- Vol. 10 (3) , 222-229
Cushing’s disease: Results of treatment and factors affecting outcome
To analyze the therapeutic results of intervention and the factors affecting the outcome of patients with Cushing's disease (CD) cared for at the All Indian Institute of Medical Science (AIIMS), New Delhi. Patients with Cushing's disease treated at a teritiary care centre from January 2000 to December 2009 were prospectively studied. Ninety-seven patients received treatment for CD during this period. Mean duration of follow-up was 3.4 ± 2.2 (mean ± SD) years. Eighty-one patients (83.5%) underwent transsphenoidal surgery (TSS) as the primary treatment modality. Fifty-four patients (66.7%) went into remission after initial TSS; ten (18.5%) of them relapsed after a mean follow-up period of 2.9 ± 2.1 (mean ± SD) years. Histopathologic examination of resected tissue showed corticotroph adenoma in 48 of the 54 (88.9%) who went into remission and 17 of the 27 (63.0%) who did not go into remission after the initial TSS. Sixteen patients with severe hypercortisolism underwent bilateral adrenalectomy (BA) as a life-saving measure which was followed by pituitary surgery 6 to 12 months later. Five patients including one with a large macroadenoma required three or more procedures to achieve eucortisolism. Fifty-four out of 81 (66.7%) of our patients with CD had remission following initial TSS, ten of whom relapsed later on. Sixteen patients unerwent BA as a life-saving procedure. Factors affecting outcome were, age, gender, low dose dexamethasone suppression test cortisol value and histologic confirmation of corticotroph adenoma.
- 1 April 2010
- Published by Springer Nature in Indian Pediatrics
- Vol. 47 (4) , 356-358
Response to growth hormone therapy in adolescents with familial panhypopituitarism
Familial combined pituitary hormone deficiency is a rare endocrine disorder. We describe growth patterns of four children (3 females and 1 male) from two families with combined pituitary hormone deficiency. These children received growth hormone at ages ranging from 14.5 years to 19 years. While all the female siblings reached their target height, the male sibling was much shorter than mid parental height. The reasons for sexual dimorphism in growth patterns in these children are unclear.
- 1 April 2010
- Published by Springer Nature in Indian Pediatrics
- Vol. 47 (4) , 356-358
Response to growth hormone therapy in adolescents with familial panhypopituitarism
Familial combined pituitary hormone deficiency is a rare endocrine disorder. We describe growth patterns of four children (3 females and 1 male) from two families with combined pituitary hormone deficiency. These children received growth hormone at ages ranging from 14.5 years to 19 years. While all the female siblings reached their target height, the male sibling was much shorter than mid parental height. The reasons for sexual dimorphism in growth patterns in these children are unclear.